NEWS RELEASE

MAGEE-WOMENS HOSPITAL of UPMC ADOPTS L-DEX® TESTING FOR LYMPHOEDEMA PREVENTION PROGRAM

ImpediMed’s L-Dex® Technology Used to Aid in the Clinical Assessment and Monitoring of Female Breast Cancer Patients at Risk for Lymphoedema

Brisbane, Australia and Pittsburgh, PA., 23 November 2010—ImpediMed Limited and Magee-Womens Hospital (Magee) of UPMC today jointly announced Magee’s plan to utilize ImpediMed’s L-Dex® technology in its newly-launched Lymphoedema Screening, Early Detection and Prevention Program (LESEP). The L-Dex technology serves as an aid in the clinical assessment of breast cancer patients at risk of developing lymphoedema.

The program, under the direction of Atilla Soran, M.D., M.P.H., professor of surgery with the University of Pittsburgh School of Medicine and a practicing surgeon with Magee-Womens Surgical Associates, will incorporate a prospective model of care with pre-surgical baseline testing and quarterly surveillance of patients in order to identify early onset of lymphoedema, which is the most effective time to treat the disease.

“The progressive nature of lymphoedema mandates that we utilize emerging technologies to identify and treat the disease as early as possible,” said Dr. Soran, who initiated a specialized clinic in 2005 to provide assessment, consultation and treatment to patients with lymphoedema. “Since there is no cure for lymphoedema, risk identification and prevention are key. The bioimpedance spectroscopy (BIS) technology used in L-Dex assessment has been shown to be very sensitive in detecting the fluid changes characteristic of early stage lymphoedema. Together with patient education and other advances in treatment, our program will provide breast cancer patients with state-of-the-art care to protect their quality of life while lowering the financial cost of treating lymphoedema.”
Magee is being recognized as an inaugural member of ImpediMed’s new U.S. Lymphoedema Centers of Excellence Program. ImpediMed’s Centers of Excellence Program will recognize and collaborate with academic medical institutions across the U.S. in establishing a pre-emptive model of lymphoedema care utilizing its cleared medical device.

“We are excited to see a highly respected academic center such as Magee adopt BIS as the core assessment methodology in its Lymphoedema Program,” said Greg Brown, CEO of ImpediMed. “This provides validation of the pre-emptive model of care through the incorporation of a standardized and objective metric for aiding in the clinical assessment of extracellular fluid volume differences between the arms of female breast cancer patients. We applaud Magee’s initiative to address this important aspect of survivorship and welcome them among our first Centers of Excellence.”

Magee sees nearly 2,700 new cancer patients per year, 90 percent of which are breast cancer, gynaecologic cancer and melanoma patients.

Lymphoedema is a chronic and progressive condition that can lead to a swollen limb deformity caused by the obstruction to the flow of lymphatic fluid. More than 20 percent of cancer patients who have lymph node dissections or receive radiation therapy to their lymph nodes are at risk for developing lymphoedema. In the United States, the highest incidence of lymphoedema occur following breast cancer surgery, with between six and 30 percent of patients developing some degree of surgery site upper extremity lymphoedema. Some patients experience symptoms of swelling immediately following surgery or radiation while others do not experience symptoms for weeks, months, or even years. Worldwide, it is estimated that there are 140 to 250 million cases of lymphoedema.

About UPMC
UPMC is an $8 billion global health enterprise with almost 50,000 employees headquartered in Pittsburgh, Pa., and is transforming health care by integrating 20 hospitals, 400 doctors’ offices and outpatient sites, a health insurance services division, and international and commercial services. Affiliated with the University of Pittsburgh Schools of the Health Sciences, UPMC is redefining health care by using innovative science, technology and medicine to invent new models of accountable, cost-efficient and patient-centered care. For more information on how UPMC is taking medicine from where it is to where it needs to be, go to www.upmc.com.

About ImpediMed
ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast
cancer patients. The device is not intended to diagnose or predict lymphoedema of an extremity.

For more information, visit www.impedimed.com.

For further information contact:

Greg Brown
ImpediMed CEO
Phone: 61-7-3860-3700
Mobile: 61-4-0828-1127

L-Dex® is a trademark of ImpediMed Limited.

"L-Dex values that lie outside the normal range may indicate the early signs of lymphoedema and values that have changed +10 L-Dex units from baseline may also indicate early lymphoedema. The L-Dex scale is a tool to assist in the clinical assessment of lymphoedema by a medical provider. The L-Dex scale is not intended to diagnose or predict lymphoedema of an extremity".